Uniqure N.V. premarket gain 2.68% following divestiture of commercial manufacturing to Genezen, streamlining operations and reducing expenses.

Uniqure N.V. experienced a premarket increase of 2.68% driven by the announcement of a significant strategic move. uniQure has agreed to sell its commercial manufacturing operations to Genezen, which will streamline the company's focus and help reduce operating expenses by $40 million annually, starting in Q3 2024. This divestiture, along with the ongoing cost reduction efforts, contributed to the stock's positive performance, indicating a potential boost for the company's profitability and efficiency in the gene therapy industry.